NanoViricides, Inc., a clinical-stage company developing broad-spectrum antivirals based on host-mimetic nanomedicine, has signed a Master Services Agreement with regulatory consultant Only Orphans Cote, founded by Dr. Timothy Cote. The agreement focuses on developing an orphan drug strategy for the company's lead candidate, NV-387, and preparing related orphan drug designation applications for submission to the US FDA Office of Orphan Products Development.
The importance of this partnership lies in the potential regulatory and commercial benefits orphan drug status could provide for NV-387. Orphan drug designation offers incentives including tax credits, user-fee exemptions, and up to seven years of market exclusivity upon approval. These benefits are particularly valuable for treatments targeting rare diseases, which often face development challenges due to smaller patient populations.
NV-387 has demonstrated strong activity in lethal animal models of orthopoxvirus infections, supporting its potential for orphan designations targeting Smallpox, MPox, and Measles. The company's platform technology, licensed from TheraCour Pharma, Inc., forms the basis for its nanoviricide class of drug candidates. More information about the company's technology and programs is available at https://www.nanoviricides.com.
Beyond poxvirus applications, NanoViricides plans to develop NV-387 as a treatment for respiratory viral infections including RSV, COVID, Long COVID, and Influenza. The company's other advanced candidate, NV-HHV-1, targets Shingles treatment. NanoViricides holds exclusive perpetual licenses for TheraCour's nanomedicine technology for numerous viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue, Ebola/Marburg viruses, and certain Coronaviruses.
The company intends to pursue additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful. However, as stated in their disclosures, the path to drug development remains lengthy and capital-intensive, with no guarantee that any candidate will demonstrate sufficient effectiveness and safety for human clinical development or ultimately become a successful pharmaceutical product.
This strategic move to pursue orphan drug designation represents a calculated approach to potentially accelerate and de-risk the development pathway for NV-387. By targeting specific rare viral diseases initially, the company may establish a regulatory foothold while continuing broader development for more common viral infections. The partnership with Only Orphans Cote brings specialized regulatory expertise to navigate the orphan drug designation process, which requires demonstrating that the drug targets a condition affecting fewer than 200,000 people in the United States.
The implications extend beyond NanoViricides to the broader antiviral development landscape. Success with NV-387 could validate the company's host-mimetic nanomedicine approach and potentially provide a template for developing broad-spectrum antivirals for both common and rare viral threats. For patients with rare viral diseases that currently lack effective treatments, this development represents a potential future therapeutic option, while the broader antiviral properties of NV-387 could eventually benefit larger patient populations affected by respiratory viruses.
